CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Novavax Earns $125 Million Milestone as Sanofi Starts Phase 3 Flu-COVID Vaccine Trial

By Public Technologies
  • Novavax earned $125 million on Oct. 29, 2026, as Sanofi initiated a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
  • The trial assesses safety and immunogenicity of Nuvaxovid combined with Sanofi’s high-dose flu vaccine in adults aged 60 and older.
  • The partnership has generated more than $1 billion in revenue to date.
  • A further $75 million milestone is tied to successful completion of manufacturing technology transfer, anticipated in mid-2027.
  • A U.S. combination vaccine launch following successful clinical and regulatory completion would trigger $225 million; combination products also carry royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-120221), on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.